Neurocrine appoints Sanjay Keswani as CMO effective June 2; Roberts transitions to advisory role

NEUROCRINE BIOSCIENCES INC

Sanjay Keswani appointed CMO effective June 2, 2025; Eiry Roberts transitions to strategic advisory role after 7 years as CMO.
Keswani brings >20 yrs pharma/biotech experience; formerly CEO of ImmunoBrain, SVP at Roche, VP at BMS.
Roberts led INGREZZA expansion, crinecerfont approval as CRENESSITY, and Phase 2 studies for osavampator and NBI-1117568 now moving to registrational.
Roberts' retirement was announced in July 2023; she remained until replacement onboarded; orderly succession.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Eiry W. Roberts

Chief Medical Officer

NBIX · NEUROCRINE BIOSCIENCES INC

Effective: 2025-06-02
Successor: Sanjay Keswani
Filed: April 4, 2025, 7:59 PM ET

Dr. Keswani will succeed Dr. Roberts, who has served as Chief Medical Officer for the past seven years, and who agreed to remain with the Company in a strategic advisory role following her succession by Dr. Keswani.

Appointed

Sanjay Keswani

Chief Medical Officer

NBIX · NEUROCRINE BIOSCIENCES INC

Effective: 2025-06-02
Filed: April 4, 2025, 7:59 PM ET

On April 2, 2025, Sanjay Keswani, M.D. agreed to succeed Eiry W. Roberts, M.D. as the Chief Medical Officer of Neurocrine Biosciences, Inc. (“Neurocrine Biosciences” or the “Company”), effective June 2, 2025.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Eiry W. Roberts departed as Chief Medical Officer at NEUROCRINE BIOSCIENCES INC.

Action: succeeded
Role: Chief Medical Officer

Exact text from the filing

Dr. Keswani will succeed Dr. Roberts, who has served as Chief Medical Officer for the past seven years, and who agreed to remain with the Company in a strategic advisory role following her succession by Dr. Keswani.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Sanjay Keswani was appointed as Chief Medical Officer at NEUROCRINE BIOSCIENCES INC.

Action: appointed
Role: Chief Medical Officer

Exact text from the filing

On April 2, 2025, Sanjay Keswani, M.D. agreed to succeed Eiry W. Roberts, M.D. as the Chief Medical Officer of Neurocrine Biosciences, Inc. (“Neurocrine Biosciences” or the “Company”), effective June 2, 2025.

View on SEC.gov

NEUROCRINE BIOSCIENCES INC filing history →

Source: SEC EDGAR

accession 0000914475-25-000081

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.